Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
calcitriol + docetaxel
- Development stage
- Unknown
- Lead developer
- Paratek Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Calcitriol + docetaxel is a combination therapy investigated primarily for the treatment of metastatic androgen-independent prostate cancer (AIPC). Calcitriol is the hormonally active form of vitamin D and acts as a natural ligand for the vitamin D receptor, exerting antineoplastic effects through induction of apoptosis, cell cycle arrest, differentiation, inhibition of proliferation, invasion, and angiogenesis. Docetaxel is a taxoid antineoplastic agent that promotes microtubule assembly and stabilizes them by preventing depolymerization; this disrupts normal microtubule dynamics essential for mitosis and interphase cellular functions. The combination has shown promising efficacy in phase II clinical trials with high PSA response rates and manageable toxicity profiles similar to single-agent docetaxel. Proprietary formulations such as DN-101 have been developed to optimize calcitriol delivery in this context[2][3][5][6].
- Brand names
- Rocaltrol + Taxotere
- Other names
- DN-101 + docetaxel
02
Targets
VDR (Vitamin D receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on calcitriol + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on calcitriol + docetaxel.